Back to Journals » ClinicoEconomics and Outcomes Research » Volume 12

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

Total article views   HTML views PDF downloads Totals
8,102 Dovepress* 6,685+ 1,287 7,972
PubMed Central* 1,417 323 1,740
Totals 8,102 1,610 9,712
*Since 15 April 2020

View citations on PubMed Central and Google Scholar